• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从丙型肝炎抗体阳性供体到丙型肝炎抗体阴性受体进行尸体供肾移植后巨细胞病毒感染的发生率。

The incidence of cytomegalovirus infection after deceased-donor kidney transplantation from hepatitis-C antibody positive donors to hepatitis-C antibody negative recipients.

作者信息

Yazawa Masahiko, Fülöp Tibor, Cseprekal Orsolya, Talwar Manish, Balaraman Vasanthi, Bhalla Anshul, Azhar Ambreen, Kovesdy Csaba P, Eason James D, Molnar Miklos Z

机构信息

James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN, USA.

Division of Transplant Surgery, Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA.

出版信息

Ren Fail. 2020 Nov;42(1):1083-1092. doi: 10.1080/0886022X.2020.1835675.

DOI:10.1080/0886022X.2020.1835675
PMID:33100098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7594852/
Abstract

BACKGROUND

Deceased-donor kidney transplantation (KT) from hepatitis C (HCV)-infected donors into HCV-uninfected recipients (HCV D+/R-) could become standard care in the near future. However, HCV viral replication by viral transmission might lead to a higher incidence of cytomegalovirus (CMV) infection in these recipients.

METHODS

A national-registry-based retrospective cohort study was conducted using the Scientific Registry of Transplant Recipients (SRTR) data set. We assessed the incidence of CMV infection in HCV antibody (Ab) negative recipients receiving kidneys from HCV Ab positive (HCVAb D+/R-) and negative (HCVAb D-/R-) donors. The risk of CMV infection was analyzed by Cox regression analysis in a propensity score (PS) matched-cohort of HCVAb D+/R- ( = 950) versus HCVAb D-/R- ( = 950). Sensitivity analysis was also conducted in the entire cohort ( = 181 082).

RESULTS

The mean age at baseline was 54 years, 75% were male, and 55% of the patients were African American in PS-matched cohort. Compared to the HCVAb D-/R - patients, recipients with HCVAb D+/R - showed identical probability for the incidence of CMV infection (Hazard Ratio (HR) = 1.00, 95% Confidence Interval (CI): 0.82-1.22). In the sensitivity analysis, compared to the HCVAb D-/R - patients, the HCVAb D+/R - group had a significantly lower risk of CMV infection in the unadjusted analysis (HR = 0.75, 95%CI: 0.65-0.85), while this risk difference disappeared after the adjusted analysis (HR = 0.99, 95%CI: 0.87-1.14).

CONCLUSION

The incidence of CMV infection was similar in recipients who received HCVAb D + and HCVAb D - KT. Further studies are needed to assess this association in KT from HCV nucleic acid positive donors.

摘要

背景

在不久的将来,将丙型肝炎病毒(HCV)感染供体的死亡供体肾移植(KT)给未感染HCV的受者(HCV D+/R-)可能会成为标准治疗方法。然而,通过病毒传播导致的HCV病毒复制可能会使这些受者中巨细胞病毒(CMV)感染的发生率更高。

方法

使用移植受者科学注册系统(SRTR)数据集进行了一项基于全国登记的回顾性队列研究。我们评估了接受HCV抗体(Ab)阳性(HCVAb D+/R-)和阴性(HCVAb D-/R-)供体肾脏的HCV抗体阴性受者中CMV感染的发生率。通过Cox回归分析在倾向评分(PS)匹配队列中分析了HCVAb D+/R-(n = 950)与HCVAb D-/R-(n = 950)受者CMV感染的风险。还在整个队列(n = 181082)中进行了敏感性分析。

结果

在PS匹配队列中,基线时的平均年龄为54岁,75%为男性,55%的患者为非裔美国人。与HCVAb D-/R-患者相比,HCVAb D+/R-受者CMV感染发生率的概率相同(风险比(HR)= 1.00,95%置信区间(CI):0.82 - 1.22)。在敏感性分析中,与HCVAb D-/R-患者相比,HCVAb D+/R-组在未调整分析中CMV感染风险显著较低(HR = 0.75,95%CI:0.65 - 0.85),而在调整分析后这种风险差异消失(HR = 0.99,95%CI:0.87 - 1.14)。

结论

接受HCVAb D+和HCVAb D-肾移植的受者中CMV感染的发生率相似。需要进一步研究以评估来自HCV核酸阳性供体的肾移植中这种关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24ae/7594852/1ff6a2701851/IRNF_A_1835675_F0004_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24ae/7594852/30cf08118c92/IRNF_A_1835675_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24ae/7594852/8a4a1ad9ed88/IRNF_A_1835675_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24ae/7594852/f1fc45ffa39c/IRNF_A_1835675_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24ae/7594852/1ff6a2701851/IRNF_A_1835675_F0004_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24ae/7594852/30cf08118c92/IRNF_A_1835675_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24ae/7594852/8a4a1ad9ed88/IRNF_A_1835675_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24ae/7594852/f1fc45ffa39c/IRNF_A_1835675_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24ae/7594852/1ff6a2701851/IRNF_A_1835675_F0004_B.jpg

相似文献

1
The incidence of cytomegalovirus infection after deceased-donor kidney transplantation from hepatitis-C antibody positive donors to hepatitis-C antibody negative recipients.从丙型肝炎抗体阳性供体到丙型肝炎抗体阴性受体进行尸体供肾移植后巨细胞病毒感染的发生率。
Ren Fail. 2020 Nov;42(1):1083-1092. doi: 10.1080/0886022X.2020.1835675.
2
Impact of Cytomegalovirus Serostatus on Allograft Loss and Mortality Within the First Year After Kidney Transplantation: An Analysis of the National Transplant Registry.巨细胞病毒血清学状态对肾移植术后第一年同种异体移植肾丢失和死亡率的影响:一项国家移植登记分析
Transplant Proc. 2020 Apr;52(3):829-835. doi: 10.1016/j.transproceed.2020.01.028. Epub 2020 Feb 27.
3
CMV specific T cell immune response in hepatitis C negative kidney transplant recipients receiving transplant from hepatitis C viremic donors and hepatitis C aviremic donors.丙型肝炎病毒阴性肾移植受者接受丙型肝炎病毒血症供体和丙型肝炎病毒血症供体移植后的 CMV 特异性 T 细胞免疫反应。
Ren Fail. 2022 Dec;44(1):831-841. doi: 10.1080/0886022X.2022.2072744.
4
Factors associated with hepatitis C antibody seroconversion after transplantation of kidneys from hepatitis C infected donors to hepatitis C naïve recipients.丙型肝炎感染供体的肾脏移植给未感染丙型肝炎的受体后,与丙型肝炎抗体血清转化相关的因素。
Ren Fail. 2020 Nov;42(1):767-775. doi: 10.1080/0886022X.2020.1798784.
5
Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir.使用低剂量缬更昔洛韦预防供体阳性/受体阴性肾移植受者的迟发性巨细胞病毒感染和疾病
Transplant Proc. 2018 Jan-Feb;50(1):124-129. doi: 10.1016/j.transproceed.2017.12.025.
6
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.直接作用抗病毒预防在丙型肝炎病毒感染供体向非感染受者的肾移植中的应用:一项开放标签非随机试验。
Ann Intern Med. 2018 Apr 17;168(8):533-540. doi: 10.7326/M17-2871. Epub 2018 Mar 6.
7
Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes.丙型肝炎病毒感染供者的肾脏移植到丙型肝炎病毒阴性受者:1 年肾移植结果。
Am J Kidney Dis. 2021 May;77(5):739-747.e1. doi: 10.1053/j.ajkd.2020.10.017. Epub 2020 Dec 14.
8
Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?直接作用抗病毒药物时代丙型肝炎病毒供体对丙型肝炎病毒阳性受者肾移植结局的影响:是否需要修订肾脏供体风险指数?
Transplantation. 2020 Jun;104(6):1215-1228. doi: 10.1097/TP.0000000000002949.
9
Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.监测肾移植受者巨细胞病毒特异性免疫的诊断效用:QuantiFERON-cytomegalovirus assay。
BMC Infect Dis. 2018 Apr 16;18(1):179. doi: 10.1186/s12879-018-3075-z.
10
Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: Analysis of United States national data.丙型肝炎病毒阳性供体至丙型肝炎病毒阴性肾移植受者的长期结局及传播率:美国国家数据的分析
Clin Transplant. 2017 Oct;31(10). doi: 10.1111/ctr.13055. Epub 2017 Aug 19.

引用本文的文献

1
CMV specific T cell immune response in hepatitis C negative kidney transplant recipients receiving transplant from hepatitis C viremic donors and hepatitis C aviremic donors.丙型肝炎病毒阴性肾移植受者接受丙型肝炎病毒血症供体和丙型肝炎病毒血症供体移植后的 CMV 特异性 T 细胞免疫反应。
Ren Fail. 2022 Dec;44(1):831-841. doi: 10.1080/0886022X.2022.2072744.
2
Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?丙型肝炎病毒血症供者在肾移植中的应用:是机会还是威胁?
Ren Fail. 2022 Dec;44(1):434-449. doi: 10.1080/0886022X.2022.2047069.

本文引用的文献

1
National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys.国家趋势与 HCV 病毒血症肾脏移植的 1 年结果。
J Am Soc Nephrol. 2019 Oct;30(10):1939-1951. doi: 10.1681/ASN.2019050462. Epub 2019 Sep 12.
2
Lessons from the real world: HCV-infected donor kidney transplantation as standard practice.来自现实世界的经验教训:丙型肝炎病毒感染供体肾移植作为标准做法。
Am J Transplant. 2019 Nov;19(11):2969-2970. doi: 10.1111/ajt.15582. Epub 2019 Oct 8.
3
Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience.
从丙型肝炎感染供体向丙型肝炎阴性受者移植肾脏:单中心经验。
Am J Transplant. 2019 Nov;19(11):3046-3057. doi: 10.1111/ajt.15530. Epub 2019 Aug 2.
4
Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals.直接作用抗病毒药物时代 HCV 血清阳性非病毒血症供者和病毒血症供者来源的 HCV 阴性受者肾移植的短期结局。
Am J Transplant. 2019 Nov;19(11):3058-3070. doi: 10.1111/ajt.15496. Epub 2019 Aug 7.
5
Use of HCV-infected organs in solid organ transplantation: An ethical challenge but plausible option.在实体器官移植中使用 HCV 感染器官:伦理挑战但可行的选择。
J Viral Hepat. 2019 Dec;26(12):1362-1371. doi: 10.1111/jvh.13130. Epub 2019 Jun 10.
6
CD56-negative NK cells with impaired effector function expand in CMV and EBV co-infected healthy donors with age.随着年龄增长,在巨细胞病毒(CMV)和EB病毒(EBV)共同感染的健康供体中,效应功能受损的CD56阴性自然杀伤细胞会扩增。
Aging (Albany NY). 2019 Jan 27;11(2):724-740. doi: 10.18632/aging.101774.
7
Risks, benefits, and ethical questions associated with transplanting kidneys from hepatitis C virus-infected donors into hepatitis C virus-negative patients.将丙型肝炎病毒感染供体的肾脏移植给丙型肝炎病毒阴性患者所涉及的风险、益处及伦理问题。
Semin Dial. 2019 Mar;32(2):179-186. doi: 10.1111/sdi.12767. Epub 2018 Nov 26.
8
Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial.感染 HCV 的供肾移植至未感染受者后 12 个月的结果:单组试验。
Ann Intern Med. 2018 Sep 4;169(5):273-281. doi: 10.7326/M18-0749. Epub 2018 Aug 7.
9
Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy.丙型肝炎病毒阳性供肾移植治疗合并直接作用抗病毒治疗的丙型肝炎病毒阴性受者的成本效益分析。
Am J Transplant. 2018 Oct;18(10):2496-2505. doi: 10.1111/ajt.15054. Epub 2018 Aug 30.
10
Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis.将丙型肝炎病毒感染与未感染的肾脏移植到丙型肝炎病毒感染的受者体内:成本效益分析。
Ann Intern Med. 2018 Aug 21;169(4):214-223. doi: 10.7326/M17-3088. Epub 2018 Jul 10.